Page 102 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

78 David S. Younger

Acknowledgment

Richard B. Hayes, DDS, PhD, MPH, Professor and Director of the Epidemiology,
Division of Population Health and Environmental Medicine, NYU, provided helpful
comments and guidance in the preparation of this manuscript.

References

[1] Scott, D. G., Watts, R. A. Epidemiology and clinical features of systemic vasculitis.
Clin. Exp. Nephrol. 2013; 17:607-10.

[2] Kermani, T. A., Warrington, K. J., Crowson, C. S., et al. Large-vessel involvement in
giant cell arteritis: a population based cohort study of the incidence-trends and
prognosis. Ann. Rheum. Dis. 2012; 72:1989-1994.

[3] Salvarani, C., Cantini, F., Boiardi, L., et al. Polymyalgia rheumatic and giant cell
arteritis. N. Engl. J. Med. 2002; 347:261-271.

[4] Hunder, G. G., Bloch, D. A., Michel, B. A., et al. The American College of
Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum.
1990; 33:1122-1128.

[5] Nuenninghoff, D. M., Hunder, G. G., Christianson, T. J. H., et al. Incidence and
predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large
artery stenosis) in patients with giant cell arteritis. Arthritis Rheum. 2003; 48:3522-
3531.

[6] Gonzalez-Gay, M. A., Vazquez-Rodriguez, T. R., Lopez-Diaz, M. J., et al.
Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum.
2009; 61:1454-1461.

[7] Dunstan, E., Lester, S. L., Rischmueller, M., et al. Epidemiology of biopsy-proven giant
cell arteritis in South Australia. Int. Med. J. 2014; 44:32-39.

[8] Ninan, J., Nguyen, A. M., Cole, A., et al. Mortality in patients with biopsy-proven giant
cell arteritis: a south Australian population-based study. J. Rheumatol. 2011; 38:2215-
2217.

[9] Herlyn, K., Buckert, F., Gross, W. L., et al. Doubled prevalence rates of ANCA-
associated vasculitides and giant cell arteritis between 1994 and 2006 in northern
Germany. Rheumatology (Oxford) 2014 Jan. 13. [Epub. ahead of print].

[10] Bas-Lando, M., Breuer, G. S., Berkun, Y., et al. The incidence of giant cell arteritis in
Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin. Exp.
Rheumatol. 2007; 25(Suppl. 44):S15-S17.

[11] Kobayashi, S., Yano, T., Matsumoto, Y., et al. Clinical and epidemiologic analysis of
giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first
government-supported nationwide survey. Arthritis Rheum. 2003; 49:594-598.

[12] Abdul-Rahman, A. M., Molteno, A. C. B., Bevin, T. H. The epidemiology of giant cell
arteritis in Otago, New Zealand: a 9-year analysis. NZ Med. J. 2011; 124:44-52.

[13] Haugeberg, G., Irgens, K. A., Thomsen, R. S. No major differences in incidence of
temporal arteritis in northern and western Norway compared with reports from southern
Norway. Scand. J. Rheumatol. 2003; 32:318-319.

Complimentary Contributor Copy